학술논문
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Document Type
Article
Author
Source
In: Haemophilia . (Haemophilia, March 2024, 30(2):345-354)
Subject
Language
English
ISSN
13652516
13518216
13518216